Publications by authors named "Annika Poch"
Stem-like T cells are attractive immunotherapeutic targets in patients with cancer given their ability to proliferate and differentiate into effector progeny. Thus, identifying T cells with enhanced stemness and understanding their developmental requirements are of broad clinical and therapeutic interest. Here, we demonstrate that during acute infection, the transcriptional regulator inhibitor of DNA binding 3 (ID3) identifies stem-like T cells that are uniquely adapted to generate precursors of exhausted T (Tpex) cells in response to chronic infection or cancer.
View Article and Find Full Text PDFArticle Synopsis
- Venetoclax is a novel drug that improves outcomes for chronic lymphocytic leukemia (CLL) patients, showing that early treatment response can predict long-term success.
- Researchers used mass cytometry to analyze blood samples from CLL patients and found that venetoclax significantly reduced various CLL cell subpopulations while increasing survival proteins in the remaining cells.
- The study suggests that CLL cells quickly adapt to therapies through survival signals like the B-cell activating factor (BAFF), indicating that combining treatments might lead to more effective and lasting results.
Although cancer-associated thrombosis (CAT) is a frequent complication in patients with malignancies, its treatment remains a challenge in daily practice. Here, we report the clinical course of a 51-year-old woman presenting with a highly thrombogenic paraneoplastic coagulopathy. Despite therapeutic anticoagulation with various agents, including rivaroxaban, fondaparinux, and low-molecular-weight heparin, the patient suffered from recurrent venous and arterial thromboembolism.
View Article and Find Full Text PDF